Clinical trial
Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated…
NCT00230854 · OPKO Health, Inc., Industry · Completed
Key facts
| NCT number | NCT00230854 |
|---|---|
| Title | Study in Non-responder Hepatitis C Genotype 1 Patients With EMZ702, Pegylated Interferon and Ribavirin |
| Official title | An Open Label, Dose Escalation Study of EMZ702 in Combination With Pegylated Interferon and Ribavirin in Patients With Chronic Hepatitis C Genotype 1 Non-responsive to Prior Therapy With Pegylated Interferon and Ribavirin |
| Lead sponsor | OPKO Health, Inc., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Chronic Hepatitis C, Hepatitis, Viral, Human |
| Intervention type | Drug |
| Interventions | EMZ702 |
| Enrollment | 28 |
| Start date | Aug 1, 2005 |
| Completion | Jul 1, 2007 |
| First posted | Oct 3, 2005 |
| Last update posted | Oct 18, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: